Prostate Cancer References

Last updated: 04 July 2024
  1. American Cancer Society. Prostate cancer staging. American Cancer Society website. https://cancerstaging.org/. 2009. Accessed 16 Oct 2015.
  2. American Cancer Society. Prostate cancer prevention and early detection. American Cancer Society. http://www.cancer.org/. 2015. Accessed 04 Nov 2015.
  3. American Urological Association; Prostate-Specific Antigen Best Practice Statement Update Panel Members. PSA testing for the pretreatment staging and posttreatment management of prostate cancer: 2013 revision of 2009 best practice statement. American Urological Association. https://www.auanet.org/. 2013. Accessed 16 Oct 2015.
  4. Australian Cancer Network Management of Metastatic Prostate Cancer Working Party. Clinical practice guidelines for the management of locally advanced and metastatic prostate cancer. Cancer Council Australia and Australian Cancer Network. http://www.cancer.org.au/. 2010. Accessed 16 Oct 2015.
  5. Cassinello J, Climent MA, González del Alba A, Mellado B, Virizuela JA; Spanish Society for Medical Oncology. SEOM clinical guidelines for the treatment of metastatic prostate cancer. Clin Transl Oncol. 2014 Dec;16(12):1060-1066. doi: 10.1007/s12094-014-1225-3. Accessed 05 Nov 2015. PMID: 25319721
  6. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. American Urological Association. https://www.auanet.org/. 2015.
  7. Cooperberg MR, Pasta DJ, Elkin EP, et al. The UCSF Cancer of the Prostate Risk Assessment (CAPRA) Score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005 Jun;173(6):1938-1942. doi:10.1097/01.ju.0000158155.33890.e7. PMID: 15879786
  8. Heidenreich A, Bastian PJ, Bellmunt J, et al; European Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014 Jan;65(1):124-137. doi: 10.1016/j.eururo.2013.09.046. PMID: 24207135
  9. Mohan R, Schellhammer PF. Treatment options for localized prostate cancer. Am Fam Physician. 2011 Aug;84(4):413-420. PMID: 21842788
  10. Mottet N, Bellmunt J, Briers E, et al, for the European Association of Urology. Guidelines on prostate cancer. European Association of Urology. http://uroweb.org/. 2014.
  11. Mottet N, Bellmunt J, Briers E, et al, for the European Association of Urology (EAU). Guidelines on prostate cancer. EAU. http://uroweb.org/. 2015.
  12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. Version 1.2015. NCCN. http://www.nccn.org/. 2015.
  13. National Institute for Health and Care Excellence (NICE). Interventional procedure guidance: cryotherapy as a primary treatment for prostate cancer. NICE. http://www.nice.org.uk/. Nov 2005.
  14. National Institute for Health and Care Excellence (NICE). Interventional procedure guidance: focal therapy using cryoablation for localised prostate cancer. NICE. http://www.nice.org.uk/. Apr 2012.
  15. National Institute for Health and Care Excellence (NICE). Prostate cancer. NICE. http://www.nice.org.uk/. Jun 2015.
  16. National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and treatment. NICE. http://www.nice.org.uk/. Jan 2014.
  17. Parker C, Gillessen S, Heidenreich A, Horwich A; ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v69-v77. doi: 10.1093/annonc/mdv222. PMID: 26205393
  18. PDQ Screening and Prevention Editorial Board. Prostate Cancer Prevention (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. http://www.ncbi.nlm.nih.gov/books/NBK65968/. Feb 2015.
  19. PDQ Adult Treatment Editorial Board. Prostate Cancer Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. http://www.ncbi.nlm.nih.gov/books/NBK66036/. Aug 2015.
  20. Thompson I, Thrasher JB, Aus G, et al; AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun;177(6):2106-2131. doi: 10.1016/j.juro.2007.03.003. PMID: 17509297
  21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer version 3.2016. NCCN. https://www.nccn.org/. 26 May 2016. Accessed 20 Jul 2016.
  22. Helsen C, Van den Broeck T, Voet A, et al. Androgen receptor antagonists for prostate cancer therapy. Endocr Relat Cancer. 2014 Aug;21(4):T105-118. doi: 10.1530/ERC-13-0545. PMID: 24639562
  23. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536. PMID: 29949494
  24. Kallur KG, Ramachandra PG, Rajkumar K, et al. Clinical utility of gallium-68 PSMA PET/CT scan for prostate cancer. Indian J Nucl Med. 2017 Apr-Jun;32(2):110-117. doi: 10.4103/0972-3919.202255. PMID: 28533638
  25. US Food and Drug Administration. FDA approves enzalutamide for castration-resistant prostate cancer. US FDA. https://www.fda.gov. 16 Jul 2018.
  26. Mottet N, van den Bergh RCN, Briers E, et al. Prostate Cancer. European Association of Urology (EAU). http://uroweb.org/. 2018. Accessed 17 Aug 2018.
  27. Mottet N, van den Bergh RCN, Briers E, et al. Prostate cancer. European Association of Urology. https://uroweb.org/. 2019.
  28. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prostate cancer. Version 4.2019. NCCN. https://www.nccn.org/. Aug 2019.
  29. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prostate cancer early detection. Version 2.2019. NCCN. https://www.nccn.org/. May 2019.
  30. Paner GP, Gandhi J, Choy B, Amin MB. Essential updates in grading, morphotyping, reporting, and staging of prostate carcinoma for general surgical pathologists. Arch Pathol Lab Med. 2019 May;143(5):550-564. doi: 10.5858/arpa.2018-0334-RA. PMID: 30865487
  31. Thompson IM, Valicenti R, Albertsen PC, et al. Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA guideline. American Urological Association. https://www.auanet.org/. 2019.
  32. American Cancer Society. Prostate cancer causes, risk factors, prevention. American Cancer Society. http://www.cancer/org. 2018.
  33. American Cancer Society. Prostate cancer staging. American Cancer Society. http://www.cancer.org. 2018.
  34. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prostate cancer. Version 1.2020. NCCN. https://www.nccn.org/. Mar 2020.
  35. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prostate cancer. Version 2.2020. NCCN. https://www.nccn.org/. May 2020.
  36. European Medicines Agency. Assessment report: INN: Leuprorelin-containing depot medicinal products. European Medicines Agency. https://www.ema.europa.eu/. 14 May 2020.
  37. European Medicines Agency. New measures to avoid handling errors with leuprorelin depot medicines. European Medicines Agency. https://www.ema.europa.eu/. 26 Jun 2020.
  38. Parker C, Castro E, Fizazi K, et al; ESMO Guidelines Committee. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Sep;31(9):1119-1134. doi: 10.1016/j.annonc.2020.06.011. PMID: 32593798
  39. Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. European Association of Urology. https://uroweb.org/. 2020.
  40. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prostate cancer early detection. Version 1.2021. NCCN. https://www.nccn.org/. Jan 2021. Accessed 24 Feb 2021.
  41. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prostate cancer. Version 1.2021. NCCN. https://www.nccn.org/. Feb 2021.
  42. World Cancer Research Fund International. Worldwide cancer data. World Cancer Research Fund International. https://www.wcrf.org/. 2018.
  43. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer, part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021 Feb;79(2):263-282. doi: 10.1016/j. eururo.2020.09.046. PMID: 33039206
  44. Gonzalez Del Alba A, Mendez-Vidal MJ, Vazquez S, et al. SEOM clinical guidelines for the treatment of advanced prostate cancer. Clin Transl Oncol. 2021 May;23(5):969-979. doi: 10.1007/s12094-021-02561-5. PMID: 33625671
  45. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prostate cancer. Version 2.2021. NCCN. https://www.nccn.org/. Feb 2021.
  46. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. part 1: screening, diagnosis, & local treatment with curative intent. Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j. eururo.2020.09.042. PMID: 33172724
  47. Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN guidelines insights: prostate cancer, version 1.2021. J Natl Compr Canc Netw. 2021 Feb;19(2):134-143. doi: 10.6004/jnccn.2021.0008. PMID: 33545689
  48. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Prostate cancer. Version 3.2022. NCCN. https://www.nccn.org/. Jan 2022.
  49. Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. European Association of Eurology. https://uroweb.org/. Mar 2022.
  50. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prostate cancer. Version 2.2023. NCCN. https://www.nccn.org/. 17 Jul 2023.
  51. Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. European Association of Urology. https://uroweb.org/. 2023.
  52. Fizazi K, Gillessen S; ESMO Guidelines Committee. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. Ann Oncol. 2023 Jun;34(6):557-563. doi: 10.1016/j.annonc.2023.02.015. PMID: 36958590
  53. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prostate cancer. Version 4.2023. NCCN. https://www.nccn.org/. 07 Sep 2023.